Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: Review of the literature and treatment proposal

Journal of Child Neurology

Volumn 24, Issue 4, 2009, Pages 431-437

  Dastgir, Jahannaz ^a,b   DiMario Jr , Francis J ^a,b  

^a Division of Pediatric Infectious Diseases   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Demyelinating disease; Immunomodulator therapy; Tumor

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADOLESCENT; ARTICLE; CASE REPORT; DEMYELINATING DISEASE; DIPLOPIA; DISEASE EXACERBATION; FACIAL NERVE PARALYSIS; HEMIPLEGIA; HUMAN; HYPERREFLEXIA; MALE; MULTIPLE SCLEROSIS; MYOKYMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PLASMAPHERESIS; PRIORITY JOURNAL; REHABILITATION CARE; RELAPSE; SENSORY DYSFUNCTION; TUMEFACTIVE DEMYELINATING LESION; VERTIGO;

ACUTE DISEASE; ADOLESCENT; BRAIN; CYCLOPHOSPHAMIDE; DEMYELINATING DISEASES; FACIAL NERVE DISEASES; FRONTAL LOBE; HEMIPLEGIA; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; OCULAR MOTILITY DISORDERS; PARESIS; PONS; RECURRENCE; TREATMENT OUTCOME; VERTIGO;

EID: 64249152347     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808324769     Document Type: Article

References (40)

1. Gadoth N. Multiple sclerosis in children. Brain Dev. 2003;25:229-232.
2. Dagher AP, Smirniotopoulos J. Tumefactive demyelinating lesions. Neuroradiology. 1996;38:560-565.
3. Selkirk SM, Shi J. Relapsing-remitting tumefactive multiple sclerosis. Mult Scler. 2005;11:731-734.
4. Zalneraitis EL, Vonsattel J-P. Case 26-1998-A 15-year-old girl with hemiparesis, slurred speech, and an intracranial lesion [Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises]. N Engl J Med. 1998;339:542-549.
5. Kumar K., Toth C., Jay V. Focal plaque of demyelination mimicking cerebral tumor in a pediatric patient. Pediatr Neurosurg. 1998;29:60-63.
6. Rusin JA, Vezina LG, Chadduck WM, Chandra RS Tumoral multiple sclerosis of the cerebellum in a child. Am J Neuroradiol. 1995;16:1164-1166.
7. Puri V., Chaudhry N., Gulati P., et al. Recurrent tumefactive demyelination in a child. J Clin Neurosci. 2005;12:495-500.
8. Al-Bunyan MA Tumor-like presentation of multiple sclerosis. Saudi Med J. 2000;21:393-395.
9. Giang DW, Poduri KR, Eskin TA, et al. Multiple sclerosis masquerading as a mass lesion. Neuroradiol. 1992;34:150-154.
10. Youl BD, Kermode AG, Thompson AJ, et al. Destructive lesions in demyelinating disease. J Neurol Neurosurg Psychiat. 1991;54:288-292.
11. McAdam LC, Blaser SI, Banwell BL Pediatric tumefactive demyelination: case series and review of the literature. Pediatr Neurol. 2002;26:18-25.
12. Kepes JJ Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol. 1993;33:18-27.
13. Masdeu JC, Quinto C., Olivera C., et al. Open-ring imaging sign: Highly specific for atypical brain demyelination. Neurology. 2000;54:1427-1433.
14. Cha S., Pierce S., Knopp EA, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. Am J Neuroradiol. 2001;22:1109-1116.
15. Law M., Meltzer DE, Cha S. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology. 2002;44:986-989.
16. Saindane AM, Cha S., Law M., et al. Proton MR spectroscopy of tumefactive demyelinating lesions. Am J Neuroradiol. 2002;23:1378-1386.
17. Butteriss DJA, Ismail A., Ellison DW, Birchall D. Use of serial proton magnetic resonance spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient with multiple sclerosis. Brit J Radiol. 2003;76:662-665.
18. Enzinger C., Strasser-Fuchs S., Ropele S., et al. Tumefactive demyelinating lesions: Conventional and advanced magnetic resonance imaging. Mult Scler. 2005;11:135-139.
19. Metafratzi Z., Argyropoulou MI, Tzoufi M., et al. Conventional MRI and magnetisation transfer imaging of tumour-like multiple sclerosis in a child. Neuroradiology. 2002;44:97-99.
20. Tsui EYK, Leung WH, Chan JH, et al. Tumefactive demyelinating lesions by combined perfusion-weighted and diffusion weighted imaging. Comput Med Imag and Graph. 2002;26:343-346.
21. Ernst T., Chang L., Walot I., Huff K. Physiologic MRI of a tumefactive multiple sclerosis lesion. Neurology. 1998;51:1486-1488.
22. Erana-Rojas IE, Barboza-Quintana A., Ayala AG, Fuller GN Demyelinating pseudotumor. Ann Diagn Pathol. 2002;6:265-271.
23. Zagzag D., Miller DC, Kleinman GM, et al. Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis. Am J Surg Pathol. 1993;17:537-545.
24. Sugita Y., Terasaki M., Shigemori M., et al. Acute focal demyelinating disease simulating brain tumors: Histopathologic guidelines for an accurate diagnosis. Neuropathology. 2001;21:25-31.
25. Ness JM, Chabas D., Sadovnick AD, et al. Clinical features of children and adolescents with multiple sclerosis. Neurology. 2007;68(suppl)2:S37-S45.
26. Mao-Draayer Y., Braff S., Pendlebury W., Panitch H. Treatement of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology. 2002;59:1074-1077.
27. Waldman A., O'Connor E., Tennekoon G. Childhood multiple sclerosis: A review. Ment Retard Dev Disabil Res Rev. 2006;12:147-156.
28. Soelberg Sorensen P., Haas J., Sellebjerg F., et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63:2028-2033.
29. Pohl D., Waubant E., Banwell B., et al. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007;68(suppl2):S54-S65.
30. Takahashi I., Sawaishi Y., Takeda O., et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol. 1997;17:83-87.
31. Pohl D., Rostasy K., Gartner J., Hanefeld F. Treatement of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64:888-890.
32. Tenembaum SN, Segura MJ Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67:511-513.
33. Mikaeloff Y., Moreau T., Debouverie M., et al. Interferon-β treatment in patients with childhood-onset multiple sclerosis. J Pediatr. 2001;139:443-446.
34. Malucchi S., Sala A., Gilli F., et al. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology. 2004;62:2031-2037.
35. Jeffery DR The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. J Neurol Sci. 2004;223:41-46.
36. Gauthier SA, Weiner HL Cyclophosphamide therapy for MS. Int Mult Scler J. 2005;12:52-58.
37. Patti F., Reggio E., Palermo F., et al. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with IFN beta plus cyclophosphamide followed by interferon beta. J Neurol. 2004;251:1502-1506.
38. Yapici Z., Eraksoy M. Bilateral demyelinating tumefactive lesions in three children with hemiparesis. J Child Neurol. 2002;17:655-660.
39. Harpey JP, Renault F., Foncin JF, et al. Démyélinisation aiguë pseudotumorale a poussees regressives. Arch Fr Pediatr. 1983;40:407-409.
40. Banwell B., Shroff M., Ness JM, et al. MRI features of pediatric multiple sclerosis. Neurology. 2007;68(suppl2):S46-S53.